The clinical characteristics of patients
| Age median (range) | 65 (25–87) |
| Gender | |
| Male | 65 (50%) |
| Female | 64 (50%) |
| Tumor type | |
| Thoracic | 41 (32%) |
| Genitourinary | 30 (23%) |
| Skin | 24 (19%) |
| Breast | 11 (9%) |
| Gastrointestinal | 10 (8%) |
| Head and neck | 6 (5%) |
| Endocrine | 5 (3%) |
| Others | 2 (1%) |
| Treatment modality | |
| Monotherapy | 66 (51%) |
| Pembrolizumab | 33 |
| Nivolumab | 25 |
| Atezolizumab | 4 |
| Durvalumab | 4 |
| Ipilimumab | 1 |
| Combination of ICI and non-ICI | 39 (30%) |
| ICI and chemotherapy | 22 |
| Pembrolizumab, carboplatin, and pemetrexed | 15 |
| Pembrolizumab and eribulin | 6 |
| Pembrolizumab, fluorouracil, leucovorin, and oxaliplatin | 1 |
| ICI and targeted therapy | 7 |
| Pembrolizumab and glembatumumab vedotin | 2 |
| Pembrolizumab, abemaciclib, and anastrozole | 1 |
| Pembrolizumab and axitinib | 1 |
| Pembrolizumab and anti-cancer stem cells* | 1 |
| Atezolizumab and cabozantinib | 1 |
| Atezolizumab and bromodomain inhibitor | 1 |
| ICI and immunotherapy | 5 |
| Nivolumab and conjugated IL-2* | 2 |
| Nivolumab and anti-CSF1R* | 1 |
| Nivolumab and cancer vaccine* | 1 |
| ICI and anti-angiogenesis | 3 |
| Pembrolizumab and anti-angiopoietins* | 1 |
| Atezolizumab and bevacizumab | 1 |
| Nivolumab and bevacizumab | 1 |
| ICI and others | 2 |
| Pembrolizumab and radium-223 | 2 |
| Combination of ICIs | 24 (19%) |
| Ipilimumab and nivolumab | 21 |
| Ipilimumab and pembrolizumab | 1 |
| Ipilimumab and PD-L1 inhibitor | 1 |
| Durvalumab and tremelimumab | 1 |
| Prior ICI treatment | |
| No | 112 (87%) |
| Yes | 17 (13%) |
| Ipilimumab and nivolumab | 9 |
| Pembrolizumab | 8 |
| Nivolumab | 1 |
| Radiotherapy exposure | |
| Concurrent radiotherapy | 7 (5%) |
| Recent radiotherapy exposure (within a year) | 22 (17%) |
| No recent radiotherapy exposure | 100 (78%) |
| Treatment discontinuation, causes | 118 (90%) |
| Toxicity | 95 (81%) |
| Progression of disease | 16 (14%) |
| Death | 4 (3%) |
| Unknown | 3 (2%) |
*Investigational drug.
CSF1R, colony-stimulating factor 1 receptor; ICI, immune checkpoint inhibitor; IL-2, interleukin-2 .